CHRS
NASDAQ
$1.42
Coherus Biosciences Inc (CHRS)
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $7.80 (+449.30%)
Market Cap
$222M
Profit Margin
397.3%
P/E Ratio
0.85
Free Cash Flow Yield
-76.81%
Price Chart
Valuation
Market Cap$222M
P/E0.85
Forward P/E41.15
P/S4.77
P/B2.88
Profitability
Total Revenue (TTM)$47M
Gross Profit (TTM)$32M
EBITDA-$170M
Profit Margin397.3%
Operating Margin-293.7%
EPS$1.70
Financial Health
Free Cash Flow Yield-76.81%
Growth & Risk
Revenue 5Y CAGR-36.18%
Beta (5Y)1.60
Sharpe Ratio0.92